EA026075B1 - Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами - Google Patents
Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами Download PDFInfo
- Publication number
- EA026075B1 EA026075B1 EA201390621A EA201390621A EA026075B1 EA 026075 B1 EA026075 B1 EA 026075B1 EA 201390621 A EA201390621 A EA 201390621A EA 201390621 A EA201390621 A EA 201390621A EA 026075 B1 EA026075 B1 EA 026075B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- zeg
- binding domain
- dose
- tug
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41222910P | 2010-11-10 | 2010-11-10 | |
| PCT/EP2011/068862 WO2012062596A1 (en) | 2010-11-10 | 2011-10-27 | Prevention of adverse effects caused by cd3 specific binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201390621A1 EA201390621A1 (ru) | 2014-05-30 |
| EA026075B1 true EA026075B1 (ru) | 2017-02-28 |
Family
ID=45044532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390621A EA026075B1 (ru) | 2010-11-10 | 2011-10-27 | Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US10130638B2 (https=) |
| EP (3) | EP3831386A1 (https=) |
| JP (2) | JP6023717B2 (https=) |
| KR (1) | KR101891845B1 (https=) |
| CN (2) | CN103533943B (https=) |
| AU (3) | AU2011328393B2 (https=) |
| CA (1) | CA2816668C (https=) |
| CL (1) | CL2013001287A1 (https=) |
| CR (1) | CR20130278A (https=) |
| CY (1) | CY1118894T1 (https=) |
| DK (1) | DK2637670T4 (https=) |
| EA (1) | EA026075B1 (https=) |
| ES (2) | ES2627538T5 (https=) |
| FI (1) | FI2637670T4 (https=) |
| HR (1) | HRP20170814T4 (https=) |
| HU (1) | HUE032782T2 (https=) |
| IL (2) | IL226268B (https=) |
| LT (1) | LT2637670T (https=) |
| MA (1) | MA34726B1 (https=) |
| ME (1) | ME02722B (https=) |
| MY (1) | MY173177A (https=) |
| NZ (1) | NZ610034A (https=) |
| PH (1) | PH12013500940A1 (https=) |
| PL (1) | PL2637670T5 (https=) |
| PT (1) | PT2637670T (https=) |
| RS (1) | RS55995B2 (https=) |
| SG (2) | SG10201508789TA (https=) |
| SI (1) | SI2637670T2 (https=) |
| SM (1) | SMT201700250T1 (https=) |
| TN (1) | TN2013000250A1 (https=) |
| UA (1) | UA113397C2 (https=) |
| WO (1) | WO2012062596A1 (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| CN103533943B (zh) | 2010-11-10 | 2018-02-13 | 安进研发（慕尼黑）股份有限公司 | 由cd3特异性结合结构域导致的不良作用的预防 |
| KR102345943B1 (ko) * | 2011-04-28 | 2021-12-31 | 암젠 리서치 (뮌헨) 게엠베하 | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CA2902739C (en) * | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| MA40938A (fr) | 2014-12-05 | 2017-10-11 | Hoffmann La Roche | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| TWI731861B (zh) | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
| WO2017008169A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| CN106810611A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| BR112019011065A2 (pt) * | 2016-12-03 | 2019-10-01 | Juno Therapeutics Inc | métodos para determinação da dosagem de células t car |
| KR20180090600A (ko) | 2017-02-03 | 2018-08-13 | 주식회사 대유위니아 | 전기밥솥 |
| US12163952B2 (en) | 2017-02-27 | 2024-12-10 | Juno Therapeutics, Inc. | Determining toxicity risk in CAR T-cell therapy |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| EP3676402B1 (en) * | 2017-08-30 | 2023-12-27 | Bristol-Myers Squibb Company | A method to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| WO2019195623A2 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| UA128825C2 (uk) | 2019-03-01 | 2024-10-30 | Ксенкор, Інк. | Гетеродимерні антитіла, що зв'язують enpp3 та cd3 |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| CA3214628A1 (en) * | 2021-04-06 | 2022-10-13 | Memorial Sloan-Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023057650A1 (en) | 2021-10-10 | 2023-04-13 | Centre Hospitalier Universitaire Vaudois (Chuv) | A method for predicting side effects of drugs and vaccines |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| WO2007068354A1 (en) * | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| WO2011051307A1 (en) * | 2009-10-27 | 2011-05-05 | Micromet Ag | Dosage regimen for administering a cd19xcd3 bispecific antibody |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US20070224191A1 (en) † | 2002-12-05 | 2007-09-27 | Pdl Biopharma, Inc. | Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| PT2342227E (pt) * | 2008-11-07 | 2015-11-13 | Amgen Res Munich Gmbh | Tratamento da leucemia linfoblástica aguda |
| NZ609201A (en) * | 2010-10-27 | 2015-01-30 | Amgen Res Munich Gmbh | Means and methods for treating dlbcl |
| CN103533943B (zh) | 2010-11-10 | 2018-02-13 | 安进研发（慕尼黑）股份有限公司 | 由cd3特异性结合结构域导致的不良作用的预防 |
-
2011
- 2011-10-27 CN CN201180064622.5A patent/CN103533943B/zh active Active
- 2011-10-27 RS RS20170458A patent/RS55995B2/sr unknown
- 2011-10-27 US US13/884,497 patent/US10130638B2/en active Active
- 2011-10-27 ME MEP-2017-104A patent/ME02722B/me unknown
- 2011-10-27 SM SM20170250T patent/SMT201700250T1/it unknown
- 2011-10-27 SG SG10201508789TA patent/SG10201508789TA/en unknown
- 2011-10-27 MY MYPI2013001611A patent/MY173177A/en unknown
- 2011-10-27 JP JP2013538125A patent/JP6023717B2/ja active Active
- 2011-10-27 KR KR1020137014669A patent/KR101891845B1/ko active Active
- 2011-10-27 SG SG2013034731A patent/SG190174A1/en unknown
- 2011-10-27 LT LTEP11788077.3T patent/LT2637670T/lt unknown
- 2011-10-27 EP EP20209362.1A patent/EP3831386A1/en active Pending
- 2011-10-27 HR HRP20170814TT patent/HRP20170814T4/hr unknown
- 2011-10-27 EP EP17159560.6A patent/EP3228315B1/en active Active
- 2011-10-27 PH PH1/2013/500940A patent/PH12013500940A1/en unknown
- 2011-10-27 HU HUE11788077A patent/HUE032782T2/en unknown
- 2011-10-27 AU AU2011328393A patent/AU2011328393B2/en active Active
- 2011-10-27 SI SI201131196T patent/SI2637670T2/sl unknown
- 2011-10-27 CN CN201810044039.1A patent/CN108403702A/zh active Pending
- 2011-10-27 EP EP11788077.3A patent/EP2637670B2/en active Active
- 2011-10-27 NZ NZ610034A patent/NZ610034A/en unknown
- 2011-10-27 CA CA2816668A patent/CA2816668C/en active Active
- 2011-10-27 PT PT117880773T patent/PT2637670T/pt unknown
- 2011-10-27 WO PCT/EP2011/068862 patent/WO2012062596A1/en not_active Ceased
- 2011-10-27 ES ES11788077T patent/ES2627538T5/es active Active
- 2011-10-27 PL PL11788077.3T patent/PL2637670T5/pl unknown
- 2011-10-27 UA UAA201307130A patent/UA113397C2/uk unknown
- 2011-10-27 ES ES17159560T patent/ES2842937T3/es active Active
- 2011-10-27 EA EA201390621A patent/EA026075B1/ru not_active IP Right Cessation
- 2011-10-27 FI FIEP11788077.3T patent/FI2637670T4/fi active
- 2011-10-27 DK DK11788077.3T patent/DK2637670T4/da active
-
2013
- 2013-05-09 CL CL2013001287A patent/CL2013001287A1/es unknown
- 2013-05-09 IL IL226268A patent/IL226268B/en active IP Right Grant
- 2013-06-10 TN TNP2013000250A patent/TN2013000250A1/fr unknown
- 2013-06-10 CR CR20130278A patent/CR20130278A/es unknown
- 2013-06-10 MA MA35999A patent/MA34726B1/fr unknown
-
2016
- 2016-07-06 JP JP2016133918A patent/JP6189491B2/ja active Active
-
2017
- 2017-03-29 AU AU2017202079A patent/AU2017202079B2/en active Active
- 2017-05-08 CY CY20171100491T patent/CY1118894T1/el unknown
-
2018
- 2018-01-25 IL IL257164A patent/IL257164B/en active IP Right Grant
- 2018-02-07 AU AU2018200915A patent/AU2018200915B2/en active Active
- 2018-10-11 US US16/157,985 patent/US11633408B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999054440A1 (en) * | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| WO2007068354A1 (en) * | 2005-12-16 | 2007-06-21 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| WO2011051307A1 (en) * | 2009-10-27 | 2011-05-05 | Micromet Ag | Dosage regimen for administering a cd19xcd3 bispecific antibody |
Non-Patent Citations (11)
| Title |
|---|
| BAEUERLE P A, REINHARDT C, KUFER P: "BiTE: a new class of antibodies that recruit T-cells", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 33, no. 2, 1 January 2008 (2008-01-01), ES, pages 137 - 147, XP002667644, ISSN: 0377-8282, DOI: 10.1358/DOF.2008.033.02.1172578 * |
| BIOLOGICAL ABSTRACTS, 19 November 2010, Philadelphia, PA, US; VIARDOT ANDREAS, ET AL: "Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 mu g/m(2)/d Is Tolerable and Highly Effective" XP002667646 * |
| BIOLOGICAL ABSTRACTS, 20 November 2009, Philadelphia, PA, US; NAGORSEN DIRK , ZUGMAIER GERHARD, VIARDOT ANDREAS, ET AL: "Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 mu g/m(2)/d of BiTE (R) Antibody Blinatumomab." XP002668994 * |
| CHRISTIAN BRANDL ; CORNELIA HAAS ; SANDRINE D’ARGOUGES ; TANJA FISCH ; PETER KUFER ; KLAUS BRISCHWEIN ; NADJA PRANG ; RALF BARGOU : "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 56, no. 10, 20 February 2007 (2007-02-20), Berlin, DE, pages 1551 - 1563, XP019539092, ISSN: 1432-0851, DOI: 10.1007/s00262-007-0298-z * |
| DIRK NAGORSEN, RALF BARGOU, DOMINIK RÜTTINGER, PETER KUFER, PATRICK A. BAEUERLE, GERHARD ZUGMAIER: "Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab", LEUKEMIA AND LYMPHOMA., INFORMA HEALTHCARE, US, vol. 50, no. 6, 1 January 2009 (2009-01-01), US, pages 886 - 891, XP008128752, ISSN: 1042-8194, DOI: 10.1080/10428190902943077 * |
| GOEBELER M, ET AL: "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, vol. 95, no. Suppl. 2, 10 June 2010 (2010-06-10), IT, pages 230, XP002667641, ISSN: 0390-6078 * |
| HOFFMANN PATRICK ET AL: "Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 115, no. 1, 20 May 2005 (2005-05-20), US, pages 98 - 104, XP002335808, ISSN: 0020-7136, DOI: 10.1002/ijc.20908 * |
| NAGORSEN D, ET AL: "Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients treated with 60 microg/m²/d of BiTE® Antibody Blinatumomab", 7 December 2009 (2009-12-07), pages 1, XP002667643, Retrieved from the Internet <URL:http://www.micromet.com/Assets/ASH_poster_final_Dec_7_2009.aspx> [retrieved on 20120119] * |
| R. BARGOU: "1Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including MCL and DLBCL", 11TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA,, LUGANO SWITZERLAND, no. 11TH, 15 June 2011 (2011-06-15) - 18 June 2011 (2011-06-18), Lugano Switzerland, pages 1 - 14, XP002667645, Retrieved from the Internet <URL:http://www.micromet.com/Assets/FN_Micromet_ICML-NHL-Oral-15June.aspx> [retrieved on 20120118] * |
| VIARDOT ET AL.: "Treatment of Patients With Non-Hodgkin Lymphoma With CD19/CD3Bispecific Antibody Blinatumomab (MT103)", TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA WITH CD19/CD3BISPECIFIC ANTIBODY BLINATUMOMAB (MT103), 6 December 2010 (2010-12-06), pages 1, XP002667647, Retrieved from the Internet <URL:http://www.micromet.com/Assets/Micromet_Viardot_poster_6DEC2010.aspx> [retrieved on 20120119] * |
| WOLF, E. HOFMEISTER, R. KUFER, P. SCHLERETH, B. BAEUERLE, P.A.: "BiTEs: bispecific antibody constructs with unique anti-tumor activity", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 18, 15 September 2005 (2005-09-15), AMSTERDAM, NL, pages 1237 - 1244, XP005103829, ISSN: 1359-6446, DOI: 10.1016/S1359-6446(05)03554-3 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA026075B1 (ru) | Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами | |
| Kolesnik et al. | Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication | |
| Collongues et al. | Current and future treatment approaches for neuromyelitis optica | |
| RU2723047C2 (ru) | Средство для лечения множественной миеломы (ММ) | |
| Takeuchi et al. | Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate | |
| Corbaux et al. | Bullous diseases | |
| EP1737490B1 (en) | Methods of treating atherosclerosis | |
| US9486475B2 (en) | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | |
| Mancianti et al. | First case report of using Ofatumumab in kidney transplantation AB0 incompatible | |
| WO2025181224A1 (en) | Cd19-selective t cell engaging molecule for treating autoimmune diseases/ autoimmune conditions | |
| Eerike et al. | Immunomodulatory therapy in diabetes mellitus: A pharmacological approach | |
| HK1247811A1 (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| HK1247811B (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| HK1187279A (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| HK1187279B (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| HK1099525B (en) | Methods of treating atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG MD TJ TM |